"Response to Halassy and colleagues." Clinical Toxicology, 56(10), pp. 910–911
Disclosure statement
ME has received non-specific research funding from Micropharm Ltd. MB has received ViperaTAb for clinical studies from Micropharm Ltd.
Clinical Toxicology
Volume 56, 2018 - Issue 10
Letter to the Editor
Response to Halassy and colleagues
Michael EddlestonPharmacology, Toxicology & Therapeutics, University of Edinburgh, Edinburgh, UK; 
http://orcid.org/0000-0002-6857-3441
http://orcid.org/0000-0002-6857-3441, Thomas LambPharmacology, Toxicology & Therapeutics, University of Edinburgh, Edinburgh, UK; Correspondence[email protected]
http://orcid.org/0000-0001-6102-2981
http://orcid.org/0000-0001-6102-2981 & ![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})